Topiramate Tablet
Product Images NDC 51655-606

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 51655-606). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 606 26 Master Bottle Label Approval Rev A 05 20)

Label (51655 606 26 Master Bottle Label Approval   Rev A 05 20)
Topiramate Tablets, USP 50 mg label for oral tablets, indicating a package of 90 tablets. The label includes storage instructions at controlled room temperature, a warning to keep out of reach of children, and details of repackaging by Northwind Pharmaceuticals, Indianapolis, IN.*
FDA Label Image

Topi (Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 01)

Topi (Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 01)
Chemical structure of topiramate, showing its molecular configuration with key functional groups including the sulfamate and sugar-like ring system.*
FDA Label Image

Topi (Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 02)

Topi (Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 02)
A cumulative incidence graph showing rates over time to first seizure for Topiramate at doses of 50 mg/day and 400 mg/day. The x-axis represents time in days up to 500, and the y-axis shows cumulative rates up to 0.50. Two curves compare seizure occurrence between the two dosage groups with a noted p-value of 0.0002.*
FDA Label Image

Figure 2: Reduction In 4-week Migraine Headache Frequency(studies 10 And 11 For Adults And Adolescents) (Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 03)

Figure 2: Reduction In 4-week Migraine Headache Frequency(studies 10 And 11 For Adults And Adolescents) (Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 03)
A bar graph comparing the change from baseline to double-blind phase in average monthly migraine period rates for Placebo, Topamax 50 mg/day, Topamax 100 mg/day, and Topamax 200 mg/day. The graph shows data from two studies with statistical significance indicated by asterisks for doses 100 mg/day and 200 mg/day compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.